成都普瑞法科技开发有限公司欢迎您!
ISO ISO
CNAS CNAS
高新技术企业 高新技术企业
USP USP
知识产权管理体系认证证书 知识产权管理体系认证证书

文献列表

专业生产定制高含量植提产品和中药成分

您当前的位置:
期刊名:J HISTOCHEM CYTOCHEM.
文献编号:
文献地址: http://jhc.sagepub.com/content/63/4/270.short
发表日期:2015 Apr.


Epigallocatechin-3-Gallate Attenuates Unilateral Ureteral Obstruction-Induced Renal Interstitial Fibrosis in Mice

Yanqiu Wang;Bowen Wang ;Feng Du;Xuesong Su;Guangping Sun;Guangyu Zhou;Xiaohui Bian ,Na Liu

Abstract

The severity of tubulointerstitial fibrosis is regarded as an important determinant of renal prognosis. Therapeutic strategies targeting tubulointerstitial fibrosis have been considered to have potential in the treatment of chronic kidney disease. This study aims to evaluate the protective effects of (-)-epigallocatechin-3-gallate (EGCG), a green tea polyphenol, against renal interstitial fibrosis in mice. EGCG was administrated intraperitoneally for 14 days in a mouse model of unilateral ureteral obstruction (UUO). The results of our histological examination showed that EGCG alleviated glomerular and tubular injury and attenuated renal interstitial fibrosis in UUO mice. Furthermore, the inflammatory responses induced by UUO were inhibited, as represented by decreased macrophage infiltration and inflammatory cytokine production. Additionally, the expression of type I and III collagen in the kidney were reduced by EGCG, which indicated an inhibition of extracellular matrix accumulation. EGCG also caused an up-regulation in α-smooth muscle actin expression and a down-regulation in E-cadherin expression, indicating the inhibition of epithelial-to-mesenchymal transition. These changes were found to be in parallel with the decreased level of TGF-β1 and phosphorylated Smad. In conclusion, the present study

 received an intraperitoneal dose of 5 mg/kg EGCG (Biopurify Phytochemicals Ltd; Chengdu, China) 

相关产品